Abstract-LDL is known to increase the sensitivity of human platelets for agonists and to induce aggregation and secretion independently at high concentrations, but its mechanism of action is largely obscure. To clarify how LDL increases platelet sensitivity, cells were incubated in lipoprotein-poor plasma and treated with collagen at a concentration that induced Ϸ20% secretion of 14 C-serotonin. Preincubation with LDL (30 minutes at 37°C) enhanced secretion in a dose-dependent manner to 60Ϯ14% at a concentration of 2 g LDL protein/L. Similar stimulation by LDL was seen when secretion was induced by the thrombin receptor-activating peptide. This enhancement was strongly reduced (1) in the presence of monoclonal antibody PAC1 against activated ␣ IIb ␤ 3 , a polyclonal antibody against ␣ IIb , and in the presence of the fibrinogen peptides GRGDS and HHLGGAKQAGDV; (2) in ␣ IIb ␤ 3 -deficient platelets; and (3) after dissociation of ␣ IIb ␤ 3 . In contrast, binding of 125 I-LDL to normal platelets in the presence of PAC1, anti-␣ IIb , GRGDS, and HHLGGAKQAGDV, and to ␣ IIb ␤ 3 -deficient platelets was normal. LDL increased the surface expression of fibrinogen in lipoprotein-poor plasma and fibrinogen-free medium, suggesting that extracellular and granular fibrinogen bind to ␣ IIb ␤ 3 after platelet-LDL interaction. Platelets deficient in fibrinogen (Ͻ0.5% of normal) or von Willebrand Factor (Ͻ1% of normal) but containing normal amounts of other ligands for ␣ IIb ␤ 3 preserved responsiveness to LDL, indicating that occupancy of ␣ IIb ␤ 3 was not restricted to fibrinogen. Inhibition of protein kinase C (bisindolylmaleimide) diminished fibrinogen binding and sensitization by LDL; inhibition of tyrosine kinases (herbimycin A) left fibrinogen binding unchanged but diminished sensitization by LDL. We conclude that an increased concentration of LDL, such as observed in homozygous familial hypercholesterolemia, sensitizes platelets to stimulation by collagen and thrombin receptor-activating peptide via ligand-induced outside-in signaling through integrin-␣ IIb 
P latelets possess specific high-affinity binding sites for LDL, ranging from 1000 to 8000 copies per platelet with a dissociation constant (K D ) value between 40 and 100 nmol/L. [1] [2] [3] [4] [5] In subjects deficient in apolipoprotein (apo) B or E receptor, LDL binding to platelets is preserved, indicating that another binding site must be involved. 3 Platelet aggregation is mediated via fibrinogen binding to sites on the integrin-␣ IIb ␤ 3 complex that become exposed once the cell is activated. The same complex has been implicated in the binding of LDL because the separate subunits bound 125 I-LDL on Western blots. Results of studies in which platelets remained intact have been contradictory, describing both inhibition 2 and no effect 6 on 125 I-LDL binding by antibodies against ␤ 3 . Modification of lysine and arginine residues in apoB100 abolished LDL binding, 7 indicating that the protein moiety of LDL served as the binding locus.
Several reports have described the synergistic enhancement of platelet responses by LDL particles. LDL enhanced fibrinogen binding by ADP 8 ; aggregation, thromboxane A 2 formation, and serotonin secretion by thrombin 9, 10 ; and platelet responsiveness to epinephrine and Ca 2ϩ -ionophore. 11 Acting as an independent agonist, very low concentrations of LDL (10 mg protein/L) induced a rise in cytosolic Ca 2ϩ and inositol phosphate turnover, 12, 13 physiological concentrations induced changes in shape (0.25 to 0.5 g/L) and aggregation (Ն0.75 g/L), 14 and, at concentrations Ͼ3 g/L, LDL triggered phosphorylation of pleckstrin, the 47-kDa substrate of protein kinase C (PKC). 15 Apart from receptor-mediated signaling, LDL may affect platelets by lipid exchange. LDL is a donor of lecithins 16 and an acceptor of arachidonic acid. 17 LDL-induced sensitization is accompanied by decreased angular movement in the platelet membrane, possibly caused by cholesterol transfer, 11 and platelets enriched with cholesterol show increased arachidonic acid release and thromboxane B 2 formation. 18 Platelets from hypercholesterolemic patients are hyperresponsive (reviewed by Betteridge et al 19 ) , whereas platelets from patients with abetalipoproteinemia, lacking apoB, respond poorly to different agonists 20 or are affected by the abnormal HDLs in these patients. 21 In the current study, we investigated the synergism between LDL and a platelet agonist in more detail. Because platelets are extremely sensitive to variations in the surrounding medium, cells were suspended in lipoprotein-poor (LP) plasma to optimally preserve their responsiveness. 9 The results, which were significant at LDL concentrations equivalent to those typical of patients with homozygous familial hypercholesterolemia (Ϸ10 g LDL mass/L or more), suggest that the synergistic effects of LDL depend on the active involvement of integrin-␣ IIb ␤ 3 (glycoprotein IIb/IIIa).
Methods

Materials
LP plasma was obtained from Perimmune Inc, and BSA (demineralized) was obtained from Organon Teknika. Sepharose 2B and protein A-Sepharose were from Pharmacia Biotech, and hirudin was from Behring. 5-Hydroxy [side-chain-2-14 C] tryptamine creatinine sulfate ([ 14 C]serotonin; specific activity, 1.85 GBq/mmol) and horseradish peroxidase-linked protein A were purchased from Amersham, and Horm collagen was from Nycomed. 32 P-Phosphoric acid and enhanced chemiluminescence reagent were from NEN-Dupont. Thrombin receptor-activating peptide SFLLRN (TRAP) was synthesized with a semiautomatic peptide synthesizer (Labortec AG SP650) according to the method of van Scharrenburg et al. 22 Malonaldehyde bis-(dimethyl acetal) was from Brunschwig. Herbimycin A was from Biomol. The bisindolylmaleimide GF 109203X, okadaic acid, and N-octylglucoside were from Boehringer Mannheim. Trypsin inhibitor was from Sigma Chemical Co. Reinforced nitrocellulose sheets were from Schleicher and Schuell. Fluorescein isothiocyanate (FITC)-conjugated monoclonal antibody (mAb) P2 against the intact ␣ IIb ␤ 3 complex 23 was from Immunotech, and FITC-conjugated anti-human fibrinogen and the negative control X949-FITC were from Dako.
Antiphosphotyrosine mAb 4G10 was from Upstate Biotechnology, and anti-phosphotyrosine mAb PY20 was from Santa Cruz Biotechnology. The mAb PAC1, against the activated ␣ IIb ␤ 3 complex (immunoglobulin M), was a gift of Dr S.J. Shattil (Scripps Research Institute, La Jolla, Calif). The fibrinogen-derived peptides GRGDS and HHLGGAKQAGDV (␥ 400 -411 ) were provided by Dr H.M. Verheij (Department of Biochemistry, Utrecht University, Utrecht, Netherlands). The mAb against coagulation factor XI (XI-3) was a gift of Dr P.A.K. von dem Borne (Department of Hematology, University Hospital Utrecht). The polyclonal antibody (pAb) against ␣ IIb (IIb), mAb against GPIb (6F6), 24 and mAb RUUSPI.18 (against P-selectin) 25 were raised in our laboratory. All other chemicals used were of analytical grade.
LDL Isolation
Fresh, nonfrozen plasma from 4 donors, each containing Ͻ200 mg lipoprotein(a) [Lp(a)] per liter, was pooled, and LDL (density, 1.019 to 1.063 kg/L) was isolated by sequential flotation in a Beckman L-70 ultracentrifuge. 26 To prevent lipid modification and bacterial contamination, 0.25 mmol/L PMSF, 0.2 mmol/L thimerosal, 2 mmol/L NaN 3 , and 4 mmol/L EDTA (final concentrations) were present during the first run (20 hours, 175 000g, 10°C). Subsequent runs (20 hours, 175 000g, 10°C) were performed in the absence of additives except for NaN 3 and EDTA. LDL was filtered through a 0.45-m filter (Millipore) and subsequently dialyzed against 10 3 vol of 150 mmol/L NaCl containing 1.5 mmol/L NaN 3 and 1 mmol/L EDTA. LDL was stored at 4°C under nitrogen for no longer than 14 days and, before each experiment, dialyzed overnight against 10 4 vol of 150 mmol/L NaCl.
Analysis of LDL Preparations
The purity of LDL preparations was assessed by agarose gel electrophoresis followed by Fat Red staining (Titan Lipoprotein Gel, Helena Laboratories). Levels of apoB100 and apoA-1 were measured using the Behring Nephelometer 100. Possible oxidative modification was measured by (1) the thiobarbituric acid-reactive substances (TBARS) method using malonaldehyde bis-(dimethyl acetal) as standard 27 and (2) 
Analysis of LP Plasma
Platelet Isolation
Freshly drawn venous blood from healthy volunteers and patients with different types of bleeding disorders was collected into 0.1 vol of 130 mmol/L trisodium citrate. Donors claimed not to have taken any medication 2 weeks before blood collection. Platelet-rich plasma (PRP) was prepared by centrifugation (10 minutes, 200g, 22°C). Gel-filtered platelets (GFPs) were isolated by gel filtration through Sepharose 2B equilibrated in Ca 2ϩ -free Tyrode's solution (137 mmol/L NaCl, 2.68 mmol/L KCl, 0.42 mmol/L NaH 2 PO 4 , 1.7 mmol/L MgCl 2 , and 11.9 mmol/L NaHCO 3 , pH 7.25) containing 0.2% BSA and 5 mmol/L glucose. GFPs were adjusted to a final count of 2ϫ10 11 platelets/L.
Measurement of Dense-Granule Secretion
PRP was incubated with 1 mol/L [ 14 C]serotonin for 30 minutes at 37°C, followed by gel filtration as described above. GFPs were adjusted to pH 6.5 with acid-citrate-dextrose solution for 10 minutes at 400g. The pellet was resuspended in LP or normal plasma (10 minutes, 500g, 22°C) to a final count of 2ϫ10 11 platelets/L. Imipramine (2 mol/L) was added to prevent reuptake of [ 14 C]serotonin. Platelets were incubated with antibodies (2 mg/L) or peptides (100 mol/L) before LDL incubation (15 minutes, 37°C) as indicated in the Results section. Subsequently, platelet suspensions were incubated with 2 g of LDL protein per liter for 30 minutes at 37°C or an equal volume of 150-mmol/L NaCl unless stated otherwise. After preincubation, samples were stimulated by collagen, stirred (8 minutes, 900 rpm, 37°C), and collected in 0. [35] [36] [37] [38] Dissociation was stopped by an equimolar amount of CaCl 2 , and platelets were resuspended in LP plasma as described. Concurrently, the degree of dissociation was determined by incubating 5ϫ10 6 GFPs with 10 L of P2-FITC (50 mg/L, 30 minutes, 37°C), a mAb specific for the intact ␣ IIb ␤ 3 complex. 23 Subsequently, 500 L of Tyrode's solution containing 10 g/L of prostaglandin I 2 (pH 6.5) was added and platelets were washed once (10 minutes, 400g) and taken up in BSA-free Tyrode's solution supplemented with 1% formaldehyde. Fluorescence was measured on a Becton-Dickinson FACScan. The degree of dissociation was measured as the mean fluorescence of the treated platelets and compared with that of GFPs incubated with X949-FITC as a negative control. X949-FITC fluorescence was Ͻ0.5% of the fluorescence of P2-FITC.
Binding of 125 I-LDL to Human Platelets
LDL was labeled with 125 I according to the method by McFarlane, 39 modified by Bilheimer et al. 40 GFPs in Tyrode's solution or LP plasma were incubated with 125 I-LDL (45 minutes, 37°C), and 100-L aliquots were layered on top of 100 L of 25% (wt/vol) sucrose in Tyrode's solution in microsedimentation tubes (Sarstedt). Cells were separated from medium by centrifugation (2 minutes, 12 000g, 22°C), and both fractions were counted in a Cobra gamma-counter (Packard). Aspecific binding (Ϸ10% of total binding) was determined by addition of a 30-fold excess of unlabeled LDL and subtracted from total binding to obtain specific-binding data. 
Measurement of Platelet-Bound Fibrinogen
Pleckstrin Phosphorylation
PRP was labeled with 32 P-orthophosphoric acid (60 minutes, 37°C), and GFPs were prepared as described earlier. Platelets (10 8 cells) were incubated with the indicated LDL concentrations (30 minutes, 37°C) or 0.2 U/mL thrombin (2 minutes, 22°C) in the presence of okadaic acid (1 mol/L). The cells were centrifuged through a dibutyl/dinonylphtalate (60:40 vol/vol) layer (4 minutes, 12 000g) to remove excess LDL into sample buffer containing ␤-mercaptoethanol, SDS, and glycerol. Quantities of lysate with the same radioactivity were separated on a 10% SDS-polyacrylamide gel. Proteins were visualized by using autoradiography.
Immunoprecipitation of Tyrosine-Phosphorylated Proteins
Platelets (10 8 cells) were treated as indicated in Results, and incubation was stopped in ice-cold 10ϫ lysis buffer (1:10 vol/vol) containing 10% Nonidet P-40, 5% N-octylglucoside, 10 mmol/L Na 3 VO 4 , 20 mmol/L PMSF, 200 g/mL trypsin inhibitor, 50 mmol/L N-ethylmaleimide, and 100 mmol/L benzamidine in Tyrode's solution. Tyrosine-phosphorylated proteins were precipitated using 1 g of PY20 and protein A-Sepharose (100 L of a 1% suspension of protein A-Sepharose in lysis buffer) for 5 hours at 4°C. Precipitates were washed 5 times with lysis buffer and taken up in sample buffer. Proteins were separated by SDS-polyacrylamide gel electrophoresis (PAGE) using a 7.5% gel and transferred to a nitrocellulose membrane. Proteins were visualized by incubation with antiphosphotyrosine mAb 4G10 (0.5 g/mL, 15 hours, 4°C) and peroxidaselinked protein A (1:10 000 vol/vol, 1 hour, 4°C) and by enhanced chemiluminescence.
Patients
Five unrelated patients with Glanzmann's thrombastenia (CAS, MAV, CPW, NH, and AV), one patient with afibrinogenemia (SS), and one patient with severe von Willebrand's disease type 3 (AS) were studied. The diagnosis was based on a markedly prolonged bleeding time (Simplate, Ͼ30 minutes [normal, Ͻ8]). The case of patient CAS has been reported previously. 41 On 2-dimensional (2D) electrophoresis, neither ␣ IIb nor ␤ 3 were detectable after silver staining. Fluorescence-activated cell sorter (FACS) data revealed 0.2% ␣ IIb ␤ 3 -positive cells. Patient MAV had thrombocytopenia (72ϫ10 9 platelets/L), and a faint signal for ␣ IIb and ␤ 3 was detected on 2D gels after silver staining and radiography of labeled platelet lysate. FACS analysis revealed 0.3% ␣ IIb ␤ 3 -positive cells. The platelet fibrinogen level was normal. Patients CPW, NH, and AV had 0.4%, 0.7%, and 0.2% ␣ IIb ␤ 3 -positive platelets, respectively. In plasma from patient SS, no fibrinogen clotting activity was detectable and fibrinogen protein content was 2 mg/L 42 ; platelet fibrinogen was 10 g/10 11 cells (control, 3 mg/10 11 cells). 42 Patient AS had low factor VIII activity (1% of normal), whereas von Willebrand factor antigen was Ͻ1%, and ristocetin-induced agglutination could not be detected.
Statistics
Data are expressed as the meanϮSD with the number of observations (n) and were analyzed with Student's t test for unpaired observations. Differences were considered significant at PϽ0.05. Figure 1A illustrates the dose-response curve for collageninduced secretion of [ 14 C]serotonin for platelets resuspended in normal and LP plasma. There was a slight decrease in responsiveness, possibly due to the low concentrations of lipoproteins in LP plasma. These data indicated that GFPs resuspended in LP plasma closely resembled PRP in collagen-induced secretion responses.
Results
LDL Enhances Collagen-Induced Dense-Granule Secretion
A 30-minute preincubation (37°C) with 2 g/L LDL failed to induce secretion. However, this treatment enhanced the responsiveness to 1 mg/L collagen and increased the release of [
14 C]serotonin from Ϸ20% to 40% (1 g/L LDL) and 60% (2 g/L LDL) of maximal secretion ( Figure 1B) . Similar results were obtained with stirred suspensions stimulated with TRAP (3 mol/L): 2 g/L LDL increased [
14 C]serotonin release from 30Ϯ15% to 90Ϯ13% (nϭ4, PϽ0.001). When the suspensions were not stirred, these data were 47Ϯ5% and 75Ϯ5% (nϭ3, PϽ0.05), which indicates that the sensitization induced by LDL was not restricted to stimulation by collagen and was found both with and without concurrent aggregation.
Role of ␣ IIb ␤ 3 in LDL-Induced Sensitization
Because ␣ IIb ␤ 3 has been proposed as a binding site for LDL, 2 we investigated whether antibodies directed against ␣ IIb ␤ 3 affected the sensitization induced by LDL. Figure 2A illustrates the effect of a mAb against the activated ␣ IIb ␤ 3 complex (PAC1), a pAb against ␣ IIb (IIb), mAb against GPIb (6F6), and mAb against coagulation factor XI (XI-3). Furthermore, peptides derived from the fibrinogen ␣-chain (GRGDS, which binds to ␤ 3 ) and the fibrinogen ␥-chain (␥ 400 -411 , which binds to ␣ IIb ) 43 were used. Control experiments showed that these antibodies and peptides did not change [
14 C]serotonin secretion induced by 1 mg/L collagen in the absence of LDL provided that secretion was Ϸ20% (data not shown). A strong decrease in LDL-induced sensitization was observed with mAb PAC1 and pAb IIb. Strong inhibition was also seen with GRGDS and ␥ 400 -411 . In contrast, mAb 6F6 and mAb XI-3 (negative controls) had no effect. Thus, interference with ligand binding to exposed ␣ IIb ␤ 3 abolished the sensitization induced by LDL.
To investigate whether the inhibitory antibodies and peptides affected binding of LDL, incubations were repeated in the presence of 125 I-labeled LDL ( Figure 2B ). Binding of 125 I-LDL was unchanged in the presence of PAC1, pAb IIb, GRGDS, and ␥ 400 -411 . This suggests that the interference with LDL-induced sensitization was not the result of impaired LDL-platelet contact. This conclusion was confirmed in experiments with platelets from patients with Glanzmann's thrombastenia, who are deficient in ␣ IIb ␤ 3 . In the absence of LDL, Glanzmann's platelets responded normally to collagen, but the stimulation by LDL was only 3%, compared with 27% in concurrent incubations with normal platelets ( Figure 3A) . Separate binding studies of 125 I-LDL to platelets from 4 patients revealed a number of binding sites, B max of 4883Ϯ1855 sites per platelet, and a K D of 123Ϯ40 nmol/L ( Figure 3B) . These values were similar to those found in control subjects (B max ϭ5222Ϯ2025 sites per platelet, K D ϭ110Ϯ57 nmol/L, nϭ4). Thus, the lack of sensitization induced by LDL was accompanied by a 99% reduction in ␣ IIb ␤ 3 but a normal number of LDL-binding sites, indicating that the absence of this integrin caused the sensitization defect.
To further characterize the role of ␣ IIb ␤ 3 in LDL-induced sensitization, platelets were incubated with EGTA (2 mmol/L, 45 minutes, 37°C). This treatment is known to dissociate the complex, [35] [36] [37] [38] as confirmed by FACS analysis of P2-FITC binding, a mAb specific for the intact complex. EGTA treatment reduced the number of intact ␣ IIb ␤ 3 complexes by 76Ϯ6% (nϭ5) ( Figure 4A ). Collagen-induced [
14 C]-serotonin secretion was not affected by EGTA treatment (data not shown). However, LDL-induced sensitization was reduced from 23% to 10% ( Figure 4B ), indicating that the intact ␣ IIb ␤ 3 complex is required for LDL-induced sensitization.
LDL Initiates Outside-In Signaling Through
To characterize the role of ␣ IIb ␤ 3 in LDL-induced sensitization in more detail, platelets were incubated with LDL and ligand binding to this integrin was evaluated by FACS analysis using an FITC-labeled anti-fibrinogen antibody. LDL induced binding of fibrinogen to ␣ IIb ␤ 3 in a dosedependent manner and a proportional enhancement of collagen-induced secretion ( Figure 5 and the Table) . Because the LP plasma contained a low (Ϸ1% of normal) but still significant amount of fibrinogen, it seemed feasible that the medium was the source of fibrinogen. However, when incubations were repeated with platelets suspended in Tyrode's solution, similar data were obtained, indicating that endogenous fibrinogen could play a role in ␣ IIb ␤ 3 -mediated sensitization induced by LDL. This implied that secretion of ␣-granule contents contributed to the stimulatory effect of LDL. The secretion was small, however, ranging between 5% and 10% on the basis of expression of the ␣-granule marker P-selectin (CD62P) and taking expression induced by 20 mol/L TRAP (5 minutes) as the maximum. Restoration of a normal fibrinogen concentration (2 g/L) increased collagen-induced secretion from 34Ϯ9% to 50Ϯ8% in the absence of LDL and from 58Ϯ6% to 76Ϯ7% (nϭ4) in LDL-treated suspensions, illustrating that the stimulation was left intact.
To investigate ligand specificity of ␣ IIb ␤ 3 , the studies were repeated in LP plasma with platelets deficient in fibrinogen (0.3% of normal) and platelets deficient in von Willebrand factor (Ͻ1% of normal). The LDL-induced increase in secretion by these platelets was 53Ϯ4% and 20Ϯ3%, respec- , 22°C) , and the degree of dissociation was determined by using FACS analysis (shaded area) and compared with dissociation in untreated platelets (unshaded area). The mean fluorescence signal after EGTA decreased from 100% to 25Ϯ6% (nϭ5). B, Platelets were treated with EGTA as described above and resuspended in LP plasma. Platelets not treated with EGTA served as a positive control. After incubation with LDL (2 g/L, 30 minutes, 37°C), platelets were stimulated with collagen (1 mg/L, 8 minutes, 37°C) and the increase in tively, indicating that stimulation by LDL was preserved. Thus, other ligands for ␣ IIb ␤ 3 present in the LP plasma and the platelet ␣-granules probably replaced the deficient proteins.
Protein phosphorylation reactions have been implicated in both exposure of binding sites on ␣ IIb ␤ 3 (inside-out signaling) and activation pathways induced by ligand-occupied ␣ IIb ␤ 3 (outside-in signaling). 44 The involvement of serine/threonine kinases and tyrosine kinases was investigated using the PKC inhibitor bisindolylmaleimide and the protein tyrosine kinase inhibitor herbimycin A. 33, 34 Expression of surface-bound fibrinogen by LDL was totally inhibited by pretreatment with bisindolylmaleimide, suggesting that PKC mediated the LDL-induced exposure and ligand binding to ␣ IIb ␤ 3 . As expected, this treatment partly inhibited the secretion induced by 1 mg/L collagen alone (to 45Ϯ17%) since secretion depends on PKC activation. The enhancement in secretion by LDL was reduced to 15%. In contrast, herbimycin A failed to affect LDL-induced ligand binding to ␣ IIb ␤ 3 but strongly interfered with the effect of LDL on collagen-induced secretion (Table) .
To confirm that LDL indeed induced protein phosphorylation, 32 P incorporation in pleckstrin, a major 47-kDa substrate for PKC, and tyrosine phosphorylation of a number of proteins were measured. LDL indeed induced phosphorylation of pleckstrin ( Figure 6A and 6B) . However, this phosphorylation was apparent only in the presence of okadaic acid, an inhibitor of serine/threonine phosphatases, indicating that LDL is a very weak activator of PKC.
LDL induced tyrosine phosphorylation of several proteins ( Figure 6C ). This phosphorylation was diminished in platelets pretreated with bisindolylmaleimide, suggesting that this step occurred downstream of PKC. Tyrosine phosphorylation was also reduced in the presence of the ␥ 400 -411 peptide, indicating that ligand binding to ␣ IIb ␤ 3 contributed to outside-in signaling before stimulation with collagen.
Discussion
The data presented here indicate that 2 g/L LDL increases the sensitivity of platelets to agonists via outside-in signaling through integrin ␣ IIb ␤ 3 . This concentration is above the range of normal subjects (0.6 to 0.9 g/L) but typical of patients with hypercholesterolemia. A first step in this mechanism involves binding of LDL to specific sites on the platelet surface. The observation that antibodies and fibrinogen-derived peptides that block ligand binding to ␣ IIb ␤ 3 43 do not disturb the binding of LDL suggests that LDL-binding sites are not on or near the integrin. Also, the normal binding of LDL to platelets deficient in ␣ IIb ␤ 3 suggests a distinct LDL-binding site. These findings agree with those recently reported by Pedreño et al. 6 Curtiss and Plow 1 reported that LDL binding to platelets was unaffected by prolonged incubation with EDTA (3 mmol/L, 37°C, 2 hours), although this treatment dissociates the ␣ IIb ␤ 3 complex, 36, 37 again separating LDL-binding sites from ␣ IIb ␤ 3 . The next step is slow induction of fibrinogen binding to surface ␣ IIb ␤ 3 . This step is mediated by PKC and independent of tyrosine phosphorylations. The degree of PKC activation by LDL is small and can be detected only when dephosphorylation of pleckstrin is prevented with an inhibitor of serine/ threonine phosphatases. The fact that LDL activates PKC agrees with results reported earlier 15 and makes the LDLbinding site a true signaling receptor. The role of PKC in ␣ IIb ␤ 3 exposure agrees with the fibrinogen binding induced by phorbol ester, 45 the sensitivity of thrombin-induced fibrinogen binding to inhibitors of PKC, 46, 47 and the stoichiometric correlation of ligand binding and phosphorylation of the ␤ 3 subunit seen in thrombin-stimulated platelets. 46 On the other hand, ADP-induced ligand binding seems not to depend on PKC. 47, 48 Normally, signal generation by platelet agonists is extremely rapid, raising cytosolic Ca 2ϩ and activating PKC within seconds, which results in immediate exposure of ␣ IIb ␤ 3 and induction of secretion responses. In the current study, a relatively long incubation with LDL was required before an effect on the platelets could be observed. Even after 30 minutes of LDL-platelet contact, the release of 14 C-serotonin was the same as in LDL-free suspensions (Ͻ5% of maximal). Also, Weidtmann et al 49 reported that native LDL failed to induce dense-granule secretion. However, Kaplan et al 50 reported that ␣-granule secretion precedes dense-granule secretion at low concentrations of thrombin, collagen, and Ca 2ϩ -ionophore, resulting in release of minor amounts of granular fibrinogen. It is possible that a similar membranebound rearrangement of granular fibrinogen mediates the signaling properties of LDL illustrated in the present report. The FACS data point to 2 platelet populations, 1 free of fibrinogen and the other showing maximal binding. The same "all-or-none" response, defined as "quantal activation" by Frojmovic et al, 51 was reported earlier for platelets treated with increasing concentrations ADP.
LDL-Induced Fibrinogen Binding and Enhancement of Collagen-Induced Secretion
The third step in LDL-induced sensitization involves ligand-induced outside-in signaling through ␣ IIb ␤ 3 . This step is mediated by tyrosine phosphorylations, but concurrent involvement of PKC cannot be ruled out. Extensive outside-in signaling, as seen in aggregating platelets, is accompanied by tyrosine phosphorylation of the ␤ 3 -subunit 52 and the focal adhesion kinase pp125 FAK , 53 whereas, under nonaggregating conditions, occupied ␣ IIb ␤ 3 initiates tyrosine phosphorylation of pp50 to 68 and pp140. 54 Indeed, we found that LDL induces tyrosine phosphorylation of several proteins. The data also show that both extracellular and ␣-granular fibrinogen can serve as ligands for ␣ IIb ␤ 3 . However, a similar sensitization induced by LDL is seen with fibrinogen-free platelets and with platelets that are deficient in von Willebrand factor, a second ␣-granule protein that can bind to ␣ IIb ␤ 3 . Thus, in the absence of 1 granule-stored ligand for ␣ IIb ␤ 3 , a second ligand can occupy ␣ IIb ␤ 3 and preserve the activating properties of LDL. A likely candidate is fibronectin, which is present in ␣-granules at a relatively high concentration (3 g/10 9 platelets 55 ). Finally, LDL-induced sensitization was evaluated with a secretion test after stimulation with collagen and TRAP. It is largely uncertain how collagen induces aggregation and secretion, but phosphorylation of phospholipase C-␥2 might be a central step. 56 Similar LDL-induced activation is seen with TRAP, indicating that platelets also get sensitized for receptor-coupled G protein signaling. This agrees with results of earlier studies by Surya et al, 10 who reported that LDL increased the sensitivity of platelets to thrombin. This sensitization depended in part on cyclooxygenase activity and was unchanged after lysine modification of apoB100. Van Willigen et al 8 found that ADP-induced fibrinogen binding was strongly enhanced by LDL, but this property depended on intact apoB100-lysine residues. These findings favor 2 distinct activating mechanisms of LDL. In contrast, Malle et al 57 found no stimulation by LDL of thrombin-and collageninduced dense granule secretion, but their experimental con- Figure 6 . Influence of LDL on protein phosphorylation. A, 32 Plabeled GFPs in Tyrode's solution were incubated with LDL at the indicated LDL concentrations (30 minutes, 37°C) in the presence of okadaic acid. Platelets were lysed, and proteins were separated by SDS-PAGE. Pleckstrin phosphorylation (47 kDa) was visualized by using autoradiography. B, Quantitation of pleckstrin phosphorylation by image analysis of platelets in the presence (F) and absence (E) of okadaic acid under the conditions specified for Figure 6A . MeanϮSD, nՆ3. *PϽ0.05 versus control. **PϽ0.001 versus control. C, GFPs in Tyrode's solution were incubated without and with ␥ 400 -411 peptide or bisindolylmaleimide (Bis) as described. After incubation with LDL (2 g/L, 30 minutes, 37°C), platelets were lysed and tyrosine phosphorylated proteins were precipitated by antiphosphotyrosine mAb PY20. Proteins were separated by SDS-PAGE and visualized with antiphosphotyrosine mAb 4G10. Arrows indicate molecularweight markers.
ditions induced optimal responses, leaving little room for further stimulation by LDL.
Our results indicate that LDL increases the sensitivity of platelets to agonists via outside-in signaling through ␣ IIb ␤ 3 . This sensitization may have little effect on platelets in the circulation as long as the LDL concentration is within the normal range. In contrast, in pathological conditions, such as heterozygous familial hypercholesterolemia, 58 familial combined hyperlipidemia, 59 nephrotic syndrome 60 (1.6 to 2.0 g/L LDL), and especially homozygous familial hypercholesterolemia (3.0 to 5.5 g/L LDL), 61, 62 LDL may induce a state of hypersensitivity in the platelets that contributes to the thrombotic tendency observed in these patients.
